A collaboration between the Department of Health and Human Services and AstraZeneca is projected to make available 300 million doses of a COVID-19 vaccine, the first of which could be available as early as October, HHS today said.

The agreement is part of the White House’s Operation Warp Speed, a public-private effort to facilitate, at an unprecedented pace, the development, manufacturing and distribution of COVID-19 countermeasures. HHS says phase three clinical studies of AZD1222 are set to start in the summer. The Food and Drug Administration must still approve an emergency use authorization or licensure in order to make the vaccine available.

AZD1222 is the fourth vaccine candidate to receive HHS’ Biomedical Advanced Research and Development Authority support for late-state development and manufacturing. BARDA can provide up to $1.2 billion for vaccine manufacturing technology transfer, process development, scaled-up manufacturing and other development activities.

Related News Articles

Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…
Headline
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…
Headline
The Centers for Disease Control and Prevention is predicting a similar combined number of peak hospitalizations from COVID-19, the flu and respiratory…
Headline
The Occupational Safety and Health Administration today announced a 60-day extension of the comment period on its proposed rule to remove the remaining…